Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2024
>
CHMP approves backing for first acanthamoeba keratitis treatment
CHMP approves backing for first acanthamoeba keratitis treatment
Read also
FDA fully approves Tecartus for relapsed or refractory mantle cell lymphoma
FDA granted full approval to Tecartus for adults with relapsed or refractory mantle cell lymphoma, expanding use beyond prior BTK inhibitor exposure.
Bio Solutions advances FDA codeine screening with fingerprint study
Intelligent Bio Solutions completed a fingerprint-based codeine screen study, supporting a planned FDA 510(k) submission for U.S. clearance.
Adagene and Incyte launch MSS colorectal cancer combination trial
Adagene and Incyte will start a Phase 1 trial in 2026 testing muzastotug with INCA33890 in third-line MSS colorectal cancer patients.
India says AI will transform drug discovery and pharma regulation
India’s Department of Pharmaceuticals said AI is reshaping drug discovery, clinical development, regulation and post-market safety monitoring.
